Xeris Biopharma Holdings, Inc. (XERS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
XERS currently has 171M outstanding shares. with limited dilution risk as only 20.5M additional shares (12.0%) are authorized for issuance. The company has diluted shareholders by 15.82% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 170.5M shares outstanding |
170M | 20M |
| Nov 06, 2025 |
10-Q filing | 163.6M shares outstanding |
160M | 27M |
| May 08, 2025 |
10-Q filing | 152.4M shares outstanding |
150M | 39M |
| Mar 06, 2025 |
S-3 filing: The company is filing an S-3 registration statement to offer up to $250.0 million in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units. |
150M | 42M |
| Mar 06, 2025 |
10-K filing | 146.8M shares outstanding |
150M | 44M |
| Nov 08, 2024 |
10-Q filing | 149.0M shares outstanding |
150M | 0 |
| Aug 08, 2024 |
10-Q filing | 148.3M shares outstanding |
150M | 0 |
| May 09, 2024 |
10-Q filing | 140.5M shares outstanding |
140M | 0 |
| Mar 06, 2024 |
10-K filing | 137.7M shares outstanding |
140M | 0 |
| Nov 09, 2023 |
10-Q filing | 138.1M shares outstanding |
140M | 0 |
| Sep 27, 2023 |
8-K filing: Xeris Biopharma Holdings, Inc. will exchange $31,975,000 in aggregate principal amount of Xeris Pharmaceuticals, Inc.'s Existing Notes for $33,574,000 in aggregate principal amount of the Company's new 8.00% Convertible Senior Notes due 2028. |
140M | 0 |
| Aug 08, 2023 |
10-Q filing | 137.3M shares outstanding |
140M | 0 |
| May 09, 2023 |
10-Q filing | 137.1M shares outstanding |
140M | 0 |
| Mar 08, 2023 |
10-K filing | 135.6M shares outstanding |
140M | 0 |
| Nov 09, 2022 |
10-Q filing | 136.0M shares outstanding |
140M | 0 |
| Aug 10, 2022 |
10-Q filing | 135.5M shares outstanding |
140M | 0 |
| May 11, 2022 |
10-Q filing | 135.0M shares outstanding |
140M | 0 |
| Mar 11, 2022 |
10-K filing | 135.5M shares outstanding |
140M | 0 |
| Mar 10, 2022 |
8-K filing: Xeris Biopharma Holdings, Inc. entered into a Credit Agreement for $100 million in term loans, with potential for an additional $50 million, and issued warrants to the lenders to purchase 1,315,789 shares of common stock at $2.28 per share. |
120M | 0 |
| Jan 28, 2022 |
S-3 filing: The selling stockholder will offer the shares of Common Stock at the prevailing market prices or privately negotiated price. |
120M | 0 |
| Jan 28, 2022 |
S-3 filing: The company is registering up to $250 million of common stock, preferred stock, debt securities, warrants and/or units. |
120M | 0 |
| Nov 10, 2021 |
10-Q filing | 124.7M shares outstanding |
120M | 0 |